Navigation Links
Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate

o are not on dialysis. Additionally, data showing the equivalence of sevelamer carbonate and sevelamer hydrochloride were presented at the 2007 spring clinical meeting of the National Kidney Foundation.

About Renagel

Renagel controls serum phosphorus in patients with CKD on hemodialysis. Controlling serum phosphorus is an important element in the care of hemodialysis patients. Elevated serum phosphorus levels are common in dialysis patients and associated with increased risk of cardiovascular mortality. Renagel provides the added benefit of significant LDL cholesterol reduction (32 percent).

The National Kidney Foundation's 2003 K/DOQI guidelines for Bone Metabolism and Disease in Chronic Kidney Disease recommend sevelamer hydrochloride as a first-line treatment option to control phosphorus. Renagel is the only phosphate binder available that does not contain either calcium or a metal. It has an established safety profile, is not systemically absorbed and provides phosphorus control without the concerns of calcium or metal accumulation. Renagel is used by more than 350,000 people worldwide.

Renagel is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on hemodialysis. Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction. In a 52-week study, the most common side effects included vomiting, nausea, diarrhea, and dyspepsia. Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel.

For more information about Renagel, including complete prescribing information, please visit www.renagel.com.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diver
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:3/26/2015)... March 26, 2015 "Whether it,s our family, ... day." In a single sentence, Dr. ... officer at Pfizer,s Centers for Therapeutic Innovation ... fueling progress at America,s biopharmaceutical companies. ... with academia, patient foundations and the National Institutes of ...
(Date:3/26/2015)... 2015 Cardiologists at Beaumont Hospital, ... commercial implant of a device recently approved by the ... fibrillation. The Watchman Left Atrial Appendage Closure implant is ... to reduce the risk of stroke. Atrial ... more than 5 million Americans. Twenty percent of all ...
(Date:3/26/2015)... NORTH CHARLESTON, S.C. , March 26, 2015 ... issues and were told by their existing PACS vendor ... Memorial Hospital (CMH) determined that they needed a ... Clinch Memorial Hospital selected Avreo interWORKS due to ... that carries modern meaningful use standards through to ...
Breaking Medicine Technology:Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
... CITY, Calif., Nov. 12, 2010 AcelRx Pharmaceuticals, Inc. announced ... S-1 with the U.S. Securities and Exchange Commission (SEC) relating ... common stock. All shares of the common stock to be ... Piper Jaffray & Co. is acting as sole ...
... FARMINGDALE, N.Y., Nov. 12, 2010 Misonix, Inc. (Nasdaq: ... the art, ultrasonic medical device technology, which worldwide is ... for the first fiscal quarter ending September 30, 2010. ... and Richard Zaremba, Senior VP and Chief Financial Officer, ...
Cached Medicine Technology:Misonix Reports First Quarter Fiscal 2011 Financial Results 2Misonix Reports First Quarter Fiscal 2011 Financial Results 3Misonix Reports First Quarter Fiscal 2011 Financial Results 4Misonix Reports First Quarter Fiscal 2011 Financial Results 5Misonix Reports First Quarter Fiscal 2011 Financial Results 6
(Date:3/27/2015)... The 2015 Deep Market Research Report ... in-depth study on the current state of the ... on the Chinese situation. , The report provides ... classifications, applications and industry chain structure. The Glutathione ... and Chinese domestic situations including development trends, competitive ...
(Date:3/27/2015)... Canadian Cannabis Clinics ( http://www.cannabisclinics.ca ), Canada’s ... medical cannabis as a treatment for patients has ... dedicated to providing access to safe medical marijuana ... searching for medical marijuana treatment in legal medical ... domain for Canada. , With the partnership ...
(Date:3/27/2015)... “ VXi BlueParott Reveal ” was ... Report, which features the latest and coolest technology products ... special reporter for NewsWatch, conducted the review and shared ... eliminating 90% of ambient noise. , Today, business is ... are important to any professional, voice calls are just ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 In light ... (case number 1:15-cv-10429, U.S. District Court, District of Massachusetts; ... the Eastern District of Pennsylvania), the San Diego personal ... Helbock, A.P.C. are announcing that they are available to ... of women who were prescribed Zofran while pregnant and ...
(Date:3/26/2015)... Elfster.com, the top-rated Secret Santa generator, is proud ... capabilities to its leading Secret Santa list technology. A ... one creates of things to do before one dies, ... name. Nowadays many millennials are creating summer bucket ... , "We are greatly expanding our technology to new ...
Breaking Medicine News(10 mins):Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3Health News:Canadian Cannabis Clinics (CCC) to Join the Canada.MarijuanaDoctors.com Network 2Health News:A Device to Tune out Background Noise was Recently Featured on NewsWatch Television 2Health News:The Law Office of Melinda J. Helbock, A.P.C. Announces That It Is Now Accepting Case Reviews for Potential Zofran Birth Defect Lawsuits 2Health News:Plans for Bucket List Generator - Just In Time for Summer - Announced by Elfster 2
... 9 ULURU Inc. (NYSE Alternext: ULU) today announced the ... the Company effective immediately. Following his resignation as Chief ... Director of the Company.Renaat Van den Hooff has been appointed ... President and Chief Executive Officer. Mr. Van de Hooff ...
... /PRNewswire/ -- SecureWorks(R), one of the ... with Columbian-based ETEK International to extend its security services ... One of South America,s leading security providers, ETEK will ... include, among others, Intrusion Prevention and Detection, Security and ...
... March 9 Based on its recent analysis ... Sullivan recognizes ValveXchange, Inc. with the 2009 North ... Year Award for developing the innovative ValveXchange Heart ... valve, the patented system promises to mitigate the ...
... March 9 ProteoTech Inc. announced today that ... Dr. Luke Esposito, Director of In Vitro Screening, ... Parkinson,s Diseases, to be held in Prague, Czech Republic, March ... Snow will give an oral presentation discussing promising results pertaining ...
... Tenn., March 9 Brookdale Senior Living Inc. ... Bill Sheriff, Chief Executive Officer, and Mark Ohlendorf, Co-President ... the Company at the Barclays Capital Global Healthcare Conference ... beginning at 4:15 p.m. Eastern Time.The presentation is being ...
... March 9 DURECT Corporation (Nasdaq: DRRX ... will be presenting at the Cowen and Company 29th ... a.m. EDT. The conference is being held at ... live audio webcast of the presentation will be available ...
Cached Medicine News:Health News:ULURU Inc. Announces Senior Management Change 2Health News:SecureWorks Partners With ETEK International to Provide Security Services to the South American and Latin American Markets 2Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 2Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 3Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 4Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 5Health News:ProteoTech to Present at 9th International Conference for Alzheimer's and Parkinson's Disease - Prague, Czech Republic, March 11-15, 2009 2Health News:DURECT to Participate in Cowen and Company Healthcare Conference 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: